PATHWAYS puberty blocker trial paused after MHRA advice
If you’re following this story for class or simply to understand the facts, here’s the starting point: on 20 February 2026 the Government confirmed the PATHWAYS clinical trial into prescribing puberty blockers for children and young people has been paused after the Medicines and Healthcare products Regulatory Agency (MHRA) raised new concerns focused on participants’ wellbeing. (gov.uk)
A pause means no one will be recruited until the regulator and the trial sponsor, King’s College London, work through the issues. Officials say discussions begin next week; only when the concerns are resolved will recruitment be allowed to start. (gov.uk)
PATHWAYS is a programme, not a single study. It includes Horizon (a long‑term observational study), Trial (the puberty suppression study), Connect (brain health comparisons), and Voices. Horizon received ethics and regulatory approval in July 2025; Trial and Connect were announced later that year with plans to begin recruitment. (hra.nhs.uk)
King’s describes the PATHWAYS Trial as a randomised study comparing immediate access to puberty‑suppressing hormones with starting after 12 months. Researchers planned to recruit about 226 participants over three years to generate robust evidence on benefits and harms. (kcl.ac.uk)
Several outlets have reported more detail about the MHRA’s advice. The Guardian says the regulator recommended raising the minimum age to 14 because of unquantified long‑term biological risks; The Times reports new questions about fertility and bone health. These are media reports and will now be considered in talks between the MHRA and King’s. (theguardian.com)
Why does this trial matter? NHS England stopped routine prescribing of puberty blockers for under‑18s in March 2024 after reviewing low‑certainty evidence. In December 2024 ministers made the emergency ban on new private prescriptions indefinite, with a review due in 2027. Any use in England is therefore confined to research such as PATHWAYS. (gov.uk)
Quick explainer for your notes: the MHRA is the UK’s independent regulator for medicines and medical devices. It can request changes to trial protocols, set conditions for recruitment, or pause studies while safety questions are addressed, all to ensure benefits outweigh risks. (gov.uk)
What this means for families now: if you were waiting to hear about taking part, recruitment is on hold until the MHRA’s concerns are resolved. People already receiving these medicines via the NHS for gender incongruence can continue; the indefinite order targets new supply, not existing NHS patients. (gov.uk)
Media‑literacy check you can share with students: a pause is not the same as a cancellation. The Government’s statement makes clear that the trial will proceed only if expert scientific and clinical advice concludes it is both safe and necessary-so decisions now hinge on evidence, not headlines. (gov.uk)
What to watch next in your timelines and briefings: if King’s and the MHRA agree adjustments-such as age thresholds, monitoring plans or consent processes-those amendments would go back through research ethics and regulatory checks before any participants are enrolled. (kcl.ac.uk)
Where did the research ask come from? The 2024 Cass Review recommended formal trials and a wider research programme to understand outcomes for all young people in specialist gender services, and NHS England has been implementing those recommendations. (england.nhs.uk)
Understanding the evidence debate for class discussion: NICE’s 2020 review, updated in 2023, judged existing studies small, uncontrolled and low‑certainty on mental health and dysphoria outcomes, with concerns about bone density. That weak evidence base is precisely why PATHWAYS was commissioned. (gov.uk)